Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...
Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...
First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total ...
Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy reviving an old treatment.
Glenis Scadding still remembers one of her first patients for sublingual immunotherapy, forty years later. His hay fever was ...
One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable ...
Insights from the BSAC New Agents Conference focused on emergent fungal and viral disease threats and therapeutic innovations ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient ...
Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
T he recent reimbursement of Bimzelx (bimekizumab) in Ireland represents an important step forward in access to treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results